This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors
Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent.
Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study
Subject does not meet the criteria specified in the parent protocol for continued treatment on study.